{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3A+Sterile+Saline&page=13",
    "query": {
      "intervention": "Placebo: Sterile Saline",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 485,
    "total_pages": 49,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3A+Sterile+Saline&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3A+Sterile+Saline&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T00:19:32.358Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05525546",
      "title": "Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Risk Reduction"
      ],
      "interventions": [
        {
          "name": "Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 82,
      "start_date": "2022-08-15",
      "completion_date": "2023-06-12",
      "has_results": false,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-25T00:19:32.358Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05525546"
    },
    {
      "nct_id": "NCT01127464",
      "title": "DCVax Plus Poly ICLC in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-1 Infection",
        "HIV Infection",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "DCVax-001",
          "type": "DRUG"
        },
        {
          "name": "Poly-ICLC",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rockefeller University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 43,
      "start_date": "2010-05",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2014-05-08",
      "last_synced_at": "2026-10-25T00:19:32.358Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01127464"
    },
    {
      "nct_id": "NCT01612221",
      "title": "Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Patients at Risk for Melanoma"
      ],
      "interventions": [
        {
          "name": "N-acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "Placebo arm",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2012-09",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2017-07-31",
      "last_synced_at": "2026-10-25T00:19:32.358Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01612221"
    },
    {
      "nct_id": "NCT01684410",
      "title": "Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Alpha-1 HC 100 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alpha-1 HC 200 mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2012-08",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2016-02-08",
      "last_synced_at": "2026-10-25T00:19:32.358Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01684410"
    },
    {
      "nct_id": "NCT04966871",
      "title": "Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "PfSPZ Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PfSPZ Challenge (7G8) for CHMI",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanaria Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 54,
      "start_date": "2021-09-27",
      "completion_date": "2022-06-21",
      "has_results": false,
      "last_update_posted_date": "2022-07-18",
      "last_synced_at": "2026-10-25T00:19:32.358Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04966871"
    },
    {
      "nct_id": "NCT05330975",
      "title": "A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1345",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Afluria® Quadrivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.214",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 3317,
      "start_date": "2022-04-01",
      "completion_date": "2024-11-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-30",
      "last_synced_at": "2026-10-25T00:19:32.358Z",
      "location_count": 62,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Garden Grove, California + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05330975"
    },
    {
      "nct_id": "NCT03705234",
      "title": "A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atherosclerotic Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Inclisiran",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oxford",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 16124,
      "start_date": "2018-10-30",
      "completion_date": "2049-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-10-25T00:19:32.358Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03705234"
    },
    {
      "nct_id": "NCT06347016",
      "title": "Study of Plozasiran in Adults With Severe Hypertriglyceridemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Plozasiran Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arrowhead Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 311,
      "start_date": "2024-07-23",
      "completion_date": "2026-09-10",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-25T00:19:32.358Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06347016"
    },
    {
      "nct_id": "NCT01336699",
      "title": "Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Shigella Infection"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "WRSs2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "WRSs3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 89,
      "start_date": "2013-01-07",
      "completion_date": "2015-05-12",
      "has_results": false,
      "last_update_posted_date": "2019-01-28",
      "last_synced_at": "2026-10-25T00:19:32.358Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01336699"
    },
    {
      "nct_id": "NCT05734716",
      "title": "Colorado-Oregon Altitude Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute Mountain Sickness"
      ],
      "interventions": [
        {
          "name": "Erythropoietin",
          "type": "DRUG"
        },
        {
          "name": "Iron sucrose (Venofer)",
          "type": "DRUG"
        },
        {
          "name": "Sterile Sodium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oregon",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 121,
      "start_date": "2021-02-17",
      "completion_date": "2023-01-01",
      "has_results": false,
      "last_update_posted_date": "2023-03-10",
      "last_synced_at": "2026-10-25T00:19:32.358Z",
      "location_count": 2,
      "location_summary": "Leadville, Colorado • Eugene, Oregon",
      "locations": [
        {
          "city": "Leadville",
          "state": "Colorado"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05734716"
    }
  ]
}